HMGB3 and ovarian carcinoma: Moreover, at 120 h, both the A2780 and A2780/CP70 cells show a negative fold change in cisplatin lesions over time, while the HMGB3-depleted A2780/CP70 cells show a positive fold change in lesions over time, suggesting that HMGB3 may be facilitating efficient cisplatin–DNA adduct removal in A2780/CP70 cisplatin-resistant ovarian cancer cells.